Form 4: Halozyme Therapeutics SVP, Chief Technical Officer Michael J. LaBarre Reports Stock Transactions

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports the sale and exercise of common stock options under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 27 and 28, 2024, Michael J. LaBarre, the SVP, Chief Technical Officer of Halozyme Therapeutics, executed transactions involving the company's common stock.
• These transactions included the sale of 10,000 shares at a price of $39.946 on February 27, 2024, and the sale of 2,529 shares at a price of $39.559 on February 28, 2024.
• Additionally, on February 28, 2024, LaBarre exercised options to purchase 7,471 shares at a price of $8.11 and sold those shares at a weighted average price of $39.542.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 9, 2023.
• Following these transactions, LaBarre directly owns 156,558 shares of common stock and options to purchase 68,156 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-arranged trading plan and do not necessarily indicate a change in the executive's confidence in the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Comparing LaBarre's transactions to other executives in similar biotech companies, the scale of these transactions appears typical for executives exercising stock options and selling shares under pre-arranged trading plans.
• For example, executives at companies like Regeneron or Amgen often utilize 10b5-1 plans to manage their stock holdings, and their Form 4 filings show similar patterns of option exercises and sales.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• However, the pre-arranged nature of the transactions should mitigate any significant concerns.

Key Dates